Treating Prostate Cancer by Antibody–Drug Conjugates
Prostate cancer is the most frequent malignancy in the worldwide male population; it is also one of the most common among all the leading cancer-related death causes. In the last two decades, the therapeutic scenario of metastatic castration-resistant prostate cancer has been enriched by the use of...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-02-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/4/1551 |
| _version_ | 1797415455400394752 |
|---|---|
| author | Matteo Rosellini Matteo Santoni Veronica Mollica Alessandro Rizzo Alessia Cimadamore Marina Scarpelli Nadia Storti Nicola Battelli Rodolfo Montironi Francesco Massari |
| author_facet | Matteo Rosellini Matteo Santoni Veronica Mollica Alessandro Rizzo Alessia Cimadamore Marina Scarpelli Nadia Storti Nicola Battelli Rodolfo Montironi Francesco Massari |
| author_sort | Matteo Rosellini |
| collection | DOAJ |
| description | Prostate cancer is the most frequent malignancy in the worldwide male population; it is also one of the most common among all the leading cancer-related death causes. In the last two decades, the therapeutic scenario of metastatic castration-resistant prostate cancer has been enriched by the use of chemotherapy and androgen receptor signaling inhibitors (ARSI) and, more recently, by immunotherapy and poly(ADP–ribose) polymerase (PARP) inhibitors. At the same time, several trials have shown the survival benefits related to the administration of novel ARSIs among patients with non-castration-resistant metastatic disease along with nonmetastatic castration-resistant cancer too. Consequently, the therapeutic course of this malignancy has been radically expanded, ensuring survival benefits never seen before. Among the more recently emerging agents, the so-called “antibody–drug conjugates” (ADCs) are noteworthy because of their clinical practice changing outcomes obtained in the management of other malignancies (including breast cancer). The ADCs are novel compounds consisting of cytotoxic agents (also known as the payload) linked to specific antibodies able to recognize antigens expressed over cancer cells’ surfaces. As for prostate cancer, researchers are focusing on STEAP1, TROP2, PSMA, CD46 and B7-H3 as optimal antigens which may be targeted by ADCs. In this paper, we review the pivotal trials that have currently changed the therapeutic approach to prostate cancer, both in the nonmetastatic castration-resistant and metastatic settings. Therefore, we focus on recently published and ongoing trials designed to investigate the clinical activity of ADCs against prostate malignancy, characterizing these agents. Lastly, we briefly discuss some ADCs-related issues with corresponding strategies to overwhelm them, along with future perspectives for these promising novel compounds. |
| first_indexed | 2024-03-09T05:48:50Z |
| format | Article |
| id | doaj.art-1edf7ae0de6042e1a91d959f2d92251e |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T05:48:50Z |
| publishDate | 2021-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-1edf7ae0de6042e1a91d959f2d92251e2023-12-03T12:18:52ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-02-01224155110.3390/ijms22041551Treating Prostate Cancer by Antibody–Drug ConjugatesMatteo Rosellini0Matteo Santoni1Veronica Mollica2Alessandro Rizzo3Alessia Cimadamore4Marina Scarpelli5Nadia Storti6Nicola Battelli7Rodolfo Montironi8Francesco Massari9Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, ItalyOncology Unit, Macerata Hospital, 62100 Macerata, ItalyDivision of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, ItalyDivision of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, ItalySection of Pathological Anatomy, School of Medicine, United Hospitals, Polytechnic University of the Marche Region, 60126 Ancona, ItalySection of Pathological Anatomy, School of Medicine, United Hospitals, Polytechnic University of the Marche Region, 60126 Ancona, ItalyDirezione Sanitaria Azienda Sanitaria Unica Regionale, 60122 Ancona, ItalyOncology Unit, Macerata Hospital, 62100 Macerata, ItalySection of Pathological Anatomy, School of Medicine, United Hospitals, Polytechnic University of the Marche Region, 60126 Ancona, ItalyDivision of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, ItalyProstate cancer is the most frequent malignancy in the worldwide male population; it is also one of the most common among all the leading cancer-related death causes. In the last two decades, the therapeutic scenario of metastatic castration-resistant prostate cancer has been enriched by the use of chemotherapy and androgen receptor signaling inhibitors (ARSI) and, more recently, by immunotherapy and poly(ADP–ribose) polymerase (PARP) inhibitors. At the same time, several trials have shown the survival benefits related to the administration of novel ARSIs among patients with non-castration-resistant metastatic disease along with nonmetastatic castration-resistant cancer too. Consequently, the therapeutic course of this malignancy has been radically expanded, ensuring survival benefits never seen before. Among the more recently emerging agents, the so-called “antibody–drug conjugates” (ADCs) are noteworthy because of their clinical practice changing outcomes obtained in the management of other malignancies (including breast cancer). The ADCs are novel compounds consisting of cytotoxic agents (also known as the payload) linked to specific antibodies able to recognize antigens expressed over cancer cells’ surfaces. As for prostate cancer, researchers are focusing on STEAP1, TROP2, PSMA, CD46 and B7-H3 as optimal antigens which may be targeted by ADCs. In this paper, we review the pivotal trials that have currently changed the therapeutic approach to prostate cancer, both in the nonmetastatic castration-resistant and metastatic settings. Therefore, we focus on recently published and ongoing trials designed to investigate the clinical activity of ADCs against prostate malignancy, characterizing these agents. Lastly, we briefly discuss some ADCs-related issues with corresponding strategies to overwhelm them, along with future perspectives for these promising novel compounds.https://www.mdpi.com/1422-0067/22/4/1551prostate cancerantibody drug conjugatestarget therapyPSMASTEAP1TROP2 |
| spellingShingle | Matteo Rosellini Matteo Santoni Veronica Mollica Alessandro Rizzo Alessia Cimadamore Marina Scarpelli Nadia Storti Nicola Battelli Rodolfo Montironi Francesco Massari Treating Prostate Cancer by Antibody–Drug Conjugates International Journal of Molecular Sciences prostate cancer antibody drug conjugates target therapy PSMA STEAP1 TROP2 |
| title | Treating Prostate Cancer by Antibody–Drug Conjugates |
| title_full | Treating Prostate Cancer by Antibody–Drug Conjugates |
| title_fullStr | Treating Prostate Cancer by Antibody–Drug Conjugates |
| title_full_unstemmed | Treating Prostate Cancer by Antibody–Drug Conjugates |
| title_short | Treating Prostate Cancer by Antibody–Drug Conjugates |
| title_sort | treating prostate cancer by antibody drug conjugates |
| topic | prostate cancer antibody drug conjugates target therapy PSMA STEAP1 TROP2 |
| url | https://www.mdpi.com/1422-0067/22/4/1551 |
| work_keys_str_mv | AT matteorosellini treatingprostatecancerbyantibodydrugconjugates AT matteosantoni treatingprostatecancerbyantibodydrugconjugates AT veronicamollica treatingprostatecancerbyantibodydrugconjugates AT alessandrorizzo treatingprostatecancerbyantibodydrugconjugates AT alessiacimadamore treatingprostatecancerbyantibodydrugconjugates AT marinascarpelli treatingprostatecancerbyantibodydrugconjugates AT nadiastorti treatingprostatecancerbyantibodydrugconjugates AT nicolabattelli treatingprostatecancerbyantibodydrugconjugates AT rodolfomontironi treatingprostatecancerbyantibodydrugconjugates AT francescomassari treatingprostatecancerbyantibodydrugconjugates |